|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 325 7th Street NW, 9th Floor |
Address2 |
|
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 31348-12
|
||||||||
|
6. House ID# 340040000
|
TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Jonathan Heafitz |
Date | 1/22/2024 3:51:22 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to prescription drug coverage and pharmacy benefits
Regulatory and proposed legislative changes to Medicare Part D prescription drug benefits
S.652 - Safe Step Act
S.1038 - Drug Price Transparency in Medicaid Act
S.1130 - Health Care PRICE Transparency Act
S.1131 - Drug Price Transparency Act
S.1217 - Ending the Prescription Drug Kickback Act
S.1375 - HELP Copays Act
S.1491 - Pharmacy and Medically Underserved Areas Enhancement Act
S.1967 - Patients Before Middlemen (PBM) Act
S.2052 - Protect Patient Access to Pharmacies Act
S.2129 - Ensuring Access to Lower-Cost Medicines for Seniors Act
S.2254 - Medicare PBM Accountability Act
S.2405 - Strengthening Pharmacy Access for Seniors Act
S.2406 - PBM Oversight Act
S.2408 - IMPROVE Part D Regulations Act
S.2436 - Neighborhood Options for Patients Buying Medicines (NO PBM) Act
S.2456 - Protecting Seniors from High Drug Costs Act
S.2474 - Share the Savings with Seniors Act
S.2477 - Equitable Community Access to Pharmacist Services Act
S.2493 - PBM Reporting Transparency Act
S.2939 - Pharmacy Access Oversight and Reporting Act
S.2973 - Modernizing and Ensuring PBM Accountability Act
S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act
H.R.830 - HELP Copays Act
H.R.1352 - Increasing Access to Biosimilars Act
H.R.1613 - Drug Price Transparency in Medicaid Act
H.R.1770 - Equitable Community Access to Pharmacists Act
H.R.2630 - Safe Step Act
H.R.2666 - Medicaid VBPs for Patients (MVP) Act
H.R.2670 - PBM Accountability Act
H.R.2691 - Transparent PRICE Act
H.R.2880 - Protecting Patients Against PBM Abuses Act
H.R.3262 - to amend title XI of the Social Security Act to increase transparency of certain health-related ownership information
H.R.3281 - Transparent PRICE Act
H.R.3282 - Promoting Transparency and Health Competition in Medicare Act
H.R.3285 - Fairness for Patient Medications
H.R.3561- Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act
H.R.4011 - Timely Access to Clinical Treatment Act
H.R.4881 - To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program
H.R.4883 - Medicare Common Ownership Transparency Act
H.R.5372 - Expanding Seniors Access to Lower Cost Medicines Act
H.R.5376 - Share the Savings with Seniors Act
H.R.5378 - Lower Costs More Transparency Act
H.R.5384 - Advancing Enrollment and Reducing Drug Costs Act
H.R.5385 - Medicare PBM Accountability Act
H.R.5386 - Cutting Copays Act
H.R.5393-Transparency and Fairness for Pharmacies Act
H.R.5400 - Neighborhood Options for Patients Buying Medicines (NO PBM) Act
H.R.5461 - Ensuring Access to Lower-Cost Medicines for Seniors Act
Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
JC |
Scott |
|
|
|
Kristin |
Bass |
|
|
|
Jonathan |
Heafitz |
|
|
|
Katherine |
Murphy |
|
|
|
Jocelyn |
Wiles |
|
|
|
Lucia |
Lebens |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues related to prescription drug coverage and pharmacy benefits
Issues related to the prescription drug marketplace, patents, and competition
Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits
S.113 - Prescription Pricing for the People Act
S.127 - Pharmacy Benefit Manager Transparency Act
S.142 - Preserve Access to Affordable Generics and Biosimilars Act
S.148 - Stop STALLING Act
S.150 - Affordable Prescriptions for Patients Act
S.652 - Safe Step Act
S.655 - Chronic Disease Management Act
S.727 - Insulin for All Act
S.775 - Increasing Transparency in Generic Drug Applications Act
S.954 - Affordable Insulin Now Act
S.1038 - Drug Price Transparency in Medicaid Act
S.1067 - Ensuring Timely Access to Generics Act
S.1114 - Expanding Access to Low-Cost Generics Act
S.1120 - Improved Access to Affordable Medications Act
S.1128 - Ensuring Access to Generic Medications Act
S.1130 - Health Care PRICE Transparency Act
S.1131 - Drug Price Transparency Act
S.1217 - Ending the Prescription Drug Kickback Act
S.1218 - Fair Prescription Drug Prices for Americans Act
S.1269 - INSULIN Act
S.1339 - Pharmacy Benefit Manager Reform Act
S.1375 - HELP Copays Act
S.1497 - Emergency Access to Insulin Act
S.1491 - Pharmacy and Medically Underserved Areas Enhancement Act
S.1542 - Delinking Revenue from Unfair Gouging (DRUG) Act
S.1543 - A bill to require regulations concerning the disclosure of direct and indirect compensation from entities providing pharmacy benefit management services or third party administration services
S.1967 - Patients Before Middlemen (PBM) Act
S.2052 - Protect Patient Access to Pharmacies Act
S.2129 - Ensuring Access to Lower-Cost Medicines for Seniors Act
S.2254 - Medicare PBM Accountability Act
S.2405 - Strengthening Pharmacy Access for Seniors Act
S.2406 - PBM Oversight Act
S.2408 - IMPROVE Part D Regulations Act
S.2436 - Neighborhood Options for Patients Buying Medicines (NO PBM) Act
S.2456 - Protecting Seniors from High Drug Costs Act
S.2474 - Share the Savings with Seniors Act
S.2477 - Equitable Community Access to Pharmacist Services Act
S.2493 - PBM Reporting Transparency Act
S.2666 - EPCS 2.0 Act
S.2840 - Bipartisan Primary Care and Health Workforce Act (Bruan Amendment #3 - Price Transparency Requirements)
S.2939 - Pharmacy Access Oversight and Reporting Act
S.2973 - Modernizing and Ensuring PBM Accountability Act
S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act
H.R.830 - HELP Copays Act
H.R.1352 - Increasing Access to Biosimilars Act
H.R.1488 - Affordable Insulin Now Act
H.R.1587 - Making Insulin Affordable for All Children Act
H.R.1613 - Drug Price Transparency in Medicaid Act
H.R.1770 - Equitable Community Access to Pharmacists Act
H.R.1790 - Biologics Competition Act
H.R.2630 - Safe Step Act
H.R.2666 - Medicaid VBPs for Patients (MVP) Act
H.R.2670 - PBM Accountability Act
H.R.2691 - Transparent PRICE Act
H.R.2880 - Protecting Patients Against PBM Abuses Act
H.R.3030 - Stop the Overuse of Petitions and Get Affordable Medicines to Enter Soon (STOP GAMES) Act
H.R.3134 - Emergency Access to Insulin Act
H.R.3262 - to amend title XI of the Social Security Act to increase transparency of certain health-related ownership information
H.R.3281 - Transparent PRICE Act
H.R.3282 - Promoting Transparency and Health Competition in Medicare Act
H.R.3285 - Fairness for Patient Medications
H.R.3561- Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act
H.R.3800 - Chronic Disease Flexible Coverage Act
H.R.4011 - Timely Access to Clinical Treatment Act
H.R.4507 - Transparency in Coverage Act
H.R.4508 - Hidden Fee Disclosure Act
H.R.4509 - Transparency in Billing Act
H.R.4527 - Health Data Act
H.R.4712 - Patient Right to Shop Act
H.R.4822 - Health Care Price Transparency Act
H.R.4846 - To amend the Internal Revenue Code of 1986, title XXVII of the Public Health Service Act, and the Employee Retirement Income Security Act of 1974 to provide for oversight of pharmacy benefit manager services
H.R.4881 - To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program
H.R.4883 - Medicare Common Ownership Transparency Act
H.R.5372 - Expanding Seniors Access to Lower Cost Medicines Act
H.R.5376 - Share the Savings with Seniors Act
H.R.5378 - Lower Costs More Transparency Act
H.R.5384 - Advancing Enrollment and Reducing Drug Costs Act
H.R.5385 - Medicare PBM Accountability Act
H.R.5386 - Cutting Copays Act
H.R.5393 -Transparency and Fairness for Pharmacies Act
H.R.5400 - Neighborhood Options for Patients Buying Medicines (NO PBM) Act
H.R.5461 - Ensuring Access to Lower-Cost Medicines for Seniors Act
Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
JC |
Scott |
|
|
|
Kristin |
Bass |
|
|
|
Jonathan |
Heafitz |
|
|
|
Katherine |
Murphy |
|
|
|
Jocelyn |
Wiles |
|
|
|
Lucia |
Lebens |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks
Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, pharmacy networks, and mail-service pharmacy
S.113 - Prescription Pricing for the People Act
S.127 - Pharmacy Benefit Manager Transparency Act
S.1038 - Drug Price Transparency in Medicaid Act
S.1130 - Health Care PRICE Transparency Act
S.1339 - Pharmacy Benefit Manager Reform Act
S.1491 - Pharmacy and Medically Underserved Areas Enhancement Act
S.2052 - Protect Patient Access to Pharmacies Act
S.2129 - Ensuring Access to Lower-Cost Medicines for Seniors Act
S.2254 - Medicare PBM Accountability Act
S.2405 - Strengthening Pharmacy Access for Seniors Act
S.2436 - Neighborhood Options for Patients Buying Medicines (NO PBM) Act
S.2477 - Equitable Community Access to Pharmacist Services Act
S.2493 - PBM Reporting Transparency Act
S.2666 - EPCS 2.0 Act
S.2840 - Bipartisan Primary Care and Health Workforce Act (Bruan Amendment #3 - Price Transparency Requirements)
S.2939 - Pharmacy Access Oversight and Reporting Act
S.2973 - Modernizing and Ensuring PBM Accountability Act
S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act
H.R.1613 - Drug Price Transparency in Medicaid Act
H.R.1770 - Equitable Community Access to Pharmacists Act
H.R.2670 - PBM Accountability Act
H.R.2691 - Transparent PRICE Act
H.R.2880 - Protecting Patients Against PBM Abuses Act
H.R.3262 - to amend title XI of the Social Security Act to increase transparency of certain health-related ownership information
H.R.3281 - Transparent PRICE Act
H.R.3282 - Promoting Transparency and Health Competition in Medicare Act
H.R.3561- Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act
H.R.4507 - Transparency in Coverage Act
H.R.4712 - Patient Right to Shop Act
H.R.4822 - Health Care Price Transparency Act
H.R.4883 - Medicare Common Ownership Transparency Act
H.R.5378 - Lower Costs More Transparency Act
H.R.5385 - Medicare PBM Accountability Act
H.R.5393 -Transparency and Fairness for Pharmacies Act
H.R.5400 - Neighborhood Options for Patients Buying Medicines (NO PBM) Act
Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
JC |
Scott |
|
|
|
Kristin |
Bass |
|
|
|
Jonathan |
Heafitz |
|
|
|
Katherine |
Murphy |
|
|
|
Jocelyn |
Wiles |
|
|
|
Lucia |
Lebens |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |